Insmed Incorporated (INSM)

26,18 +0,03 (+0,11%) Börsenschluss: 04:00PM EDT

Insmed Incorporated

700 US Highway 202/206
Bridgewater, NJ 08807
United States
908 977 9900
https://www.insmed.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 912

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. William H. Lewis J.D., M.B.A.	President, CEO & Chairman	1,59M	1,11M	1969
Ms. Sara M. Bonstein M.B.A.	Chief Financial Officer	810,4k	N/A	1981
Mr. Roger Adsett M.B.A.	Chief Operating Officer	1,01M	N/A	1969
Mr. John Drayton Wise M.B.A.	Chief Commercial Officer	888,85k	N/A	1975
Dr. Martina Flammer M.B.A., M.D.	Chief Medical Officer	872,29k	179,49k	1964
Mr. Brian K. Kaspar Ph.D.	Chief Scientific Officer	N/A	N/A	1974
Eleanor Barisser	Associate Director of Investor Relations	N/A	N/A	N/A
Mr. Michael Alexander Smith J.D.	Chief Legal Officer & Corporate Secretary	N/A	N/A	1978
Mandy Fahey	Executive Director of Corporate Communications	N/A	N/A	N/A
Ms. S. Nicole Schaeffer M.B.A.	Chief People Strategy Officer	660,81k	1,18M	1968

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Corporate Governance

Insmed Incorporateds ISS Governance QualityScore, Stand 1. April 2024, lautet 6. Die grundlegenden Scores sind Audit: 6, Vorstand: 5, Shareholderrechte: 9, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.